Preview

Medical Immunology (Russia)

Advanced search

HERPESVIRUS INFECTIONS AND CLINICAL-IMMUNOLOGIC INTERACTIONS IN PATIENTS WITH EARLY-ONSET ALZHEIMER’S DISEASE AND LATE-ONSET ALZHEIMER’S DISEASE

https://doi.org/10.15789/1563-0625-HIA-2168

Abstract

Alzheimer’s disease (AD) is currently the most common cause of dementia. A significant role in the pathogenesis of AD belongs to the activation of the mechanisms of neuroinflammation. There is a hypothesis that chronic infections may play a role in the maintenance of the inflammatory response in AD. The aim of this work was to study the detection rate and DNA level of herpesviruses, as well as their possible relationship with the level of the key cytokines and with clinical parameters of AD in patients with early and late onset. 30 patients with AD and 33 healthy volunteers were enrolled. The quantitative determination of DNA of CMV, EBV, HHV-6, HHV-7 was carried out by PCR. The level of cytokines and soluble IL-1β antagonist (IL-1ra) in the blood was determined by ELISA. Herpesvirus infection with increased viral load was determined if at least one of the criteria was present: 1) DNA level of EBV and/or HHV-6 > 10,000 copies/ml in saliva; 2) presence of DNA of at least one of the EBV, HHV-6, HHV-7 viruses in the blood. In the subgroup of patients with early onset and increased viral load, there was a higher increase in the levels of a number of cytokines: proinflammatory IL-8 and IL-12, a Th2-cytokine IL-4, a cytokine of the adaptive immune response IL-2. However, the level of the anti-inflammatory protein IL-1ra was lower than in the controls. These changes may indicate a dysregulation of the antiviral response, with a predominance of activation of systemic inflammation and Th2-mediated reactions. Also, in early onset AD the increased viral load was associated with lower scores on Boston naming test. The results indicate that in studies of AD mechanisms and in the search for prognostic markers of the disease, it is important to take into account the heterogeneity of AD in terms of genetic predisposition factors, risk factors, immune parameters and clinical data. Such approach is necessary for the subsequent development of personalized approaches to the prevention and treatment of AD. 

About the Authors

I. K. Malashenkova
National Research Center “Kurchatov Institute”; Federal Research and Clinical Center of Physical-Chemical Medicine, Federal Medical-Biological Agency of Russia
Russian Federation

PhD (Medicine), Head, Laboratory of Molecular Immunology and Virology, 123182, Moscow, Acad. Kurchatov sq., 1;

Leading Research Associate, Laboratory of Clinical Immunology, Moscow



D. P. Ogurtsov
National Research Center “Kurchatov Institute”; Federal Research and Clinical Center of Physical-Chemical Medicine, Federal Medical-Biological Agency of Russia
Russian Federation

PhD (Medicine), Research Associate at Laboratory of Molecular Immunology and Virology, 123182, Moscow, Acad. Kurchatov sq., 1;

Research Associate, Laboratory of Clinical Immunology, Moscow



S. A. Krynskiy
National Research Center “Kurchatov Institute”
Russian Federation

PhD (Medicine), Research Associate, Laboratory of Molecular Immunology and Virology,

Moscow



N. A. Khailov
National Research Center “Kurchatov Institute”
Russian Federation

PhD (Medicine), Senior Research Associate, Resource Center for Molecular and Cellular Biology,

Moscow



N. D. Selezneva
Mental Health Research Center
Russian Federation

PhD, MD (Medicine), Professor, Leading Research Associate, Department of Geriatric Psychiatry, 

Moscow



Ya. B. Fedorova
Mental Health Research Center
Russian Federation

PhD (Medicine), Senior Research Associate, Department of Geriatric Psychiatry, 

Moscow



E. V. Ponomareva
Mental Health Research Center
Russian Federation

PhD (Medicine), Senior Research Associate, Department of Geriatric Psychiatry,

Moscow



I. V. Kolykhalov
Mental Health Research Center
Russian Federation

PhD, MD (Medicine), Chief Research Associate, Department of Geriatric Psychiatry,

Moscow



S. I. Gavrilova
Mental Health Research Center
Russian Federation

PhD, MD (Medicine), Professor, Head, Department of Geriatric Psychiatry,

Moscow



N. A. Didkovsky
Federal Research and Clinical Center of Physical-Chemical Medicine, Federal Medical-Biological Agency of Russia
Russian Federation

PhD, MD (Medicine), Professor, Head, Laboratory of Clinical Immunology,

123182, Moscow, Acad. Kurchatov sq., 1



References

1. Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimer Dement., 2017, Vol. 13, no. 4, pp. 325-373.

2. Bourgade K., le Page A., Bocti C., Witkowski J.M., Dupuis G., Frost E.H., Tamásf F.J. Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. J. Alzheimers Dis., 2016, Vol. 50, no. 4, pp. 1227-1241.

3. Carbone I., Lazzarotto T., Ianni M., Porcellini E., Forti P., Masliah E., Gabrielli L., Licastro F. Herpes virus in Alzheimer’s disease: relation to progression of the disease. Neurobiol. Aging, 2014, Vol. 35, no. 1, pp. 122-129.

4. Didkovsky N.A., Ogurtsov D.P., Krynskiy S.A., Gurskaya O.G., Shipulina O.Y., Domonova E.A., Silveistrova O.Y., Kompaneets I.A., Zharova M., Hailov N.A., Каzanovа G.V., Malashenkova I.K. Myalgic encephalomyelitis / chronic fatigue syndrome: replication levels of lymphotropic herpesviruses and immune defense. Polyclinic, 2016, Vol. 5, no. 1, pp. 46-50. (In Russ.)

5. Honjo K., van Reekum R., Verhoeff N. Alzheimer’s disease and infection: Do infectious agents contribute to progression of Alzheimer’s disease? Alzheimers Dement., 2009, Vol. 5, no. 4, pp. 348-360.

6. Kuhla A., Ludwig S.C., Kuhla B., Münchc G., Vollmara B. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiol. Aging, 2015, Vol. 36, no. 2, pp. 753-761.

7. Malashenkova I.K., Krynskiy S.A., Mamoshina M.V., Didkovskiy N.A. APOE gene polymorphism: the impact of ApoE4 allele on systemic inflammation and its role in the pathogenesis of Alzheimer’s disease. Medical Immunology (Russia), 2018, Vol. 20, no. 3, pp. 301-310. (Russ.)] doi: 10.15789/1563-0625-2018-3-303-312.

8. Malashenkova I.K., Krynskiy S.A., Khailov N.A., Ogurtsov D.P., Chekulaeva E.I., Ponomareva E.V., Gavrilova S.I., Didkovsky N.A. Immunological variants of amnestic mild cognitive impairment. S. Korsakov Journal of Neurology and Psychiatry, 2020, Vol. 120, no. 10, pp. 60-68. (In Russ.)]

9. Malashenkova I.K., Krynskiy S.A., Khailov N.A., Ogurtsov D.P., Ponomareva E.V., Gavrilova S.I., Didkovsky N.A. Adaptive immunity, systemic inflammation and cytokine levels in patients with Alzheimer’s disease of different severity and with amnestic mild cognitive impairment. Allergologiya i immunologiya = Allergology and Immunology, 2018, Vol. 19, no. 4, pp. 206-214. (In Russ.)]

10. Malashenkova I.K., Hailov N.A., Krynskiy S.A., Ogurtsov D.P., Kazanova G.V., Velichkovskiy B.B., Selesneva N.D., Fedorova Y.B., Ponomareva E.V., Kolyhalov I.V., Gavrilova S.I., Didkovsky N.A.. Levels of proinflammatory cytokines and growth factor VEGF in patients with Alzheimer’s disease and mild cognitive impairment. Neurosci. Behav. Physiol., 2017, Vol. 47, no. 6, pp. 694-698.

11. Meraz-Ríos M.A., Franco-Bocanegra D., Toral Rios D., Campos-Peña V. Early onset Alzheimer’s disease and oxidative stress. Oxid. Med. Cell. Longev., 2014, Vol. 2014, 375968. doi: 10.1155/2014/375968.

12. Ortega-Madueño I., Garcia-Montojo M., Dominguez-Mozo M.I., Garcia-Martinez A., Arias-Leal A.M., Casanova I., Arroyo R., Alvarez-Lafuente R. Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis. PLoS One, 2014, Vol. 9, no. 8, e104836. doi: 10.1371/journal.pone.0104836.

13. Szczepanik A.M., Funes S., Petko W., Ringheim G. IL-4, IL-10 and IL-13 modulate A beta (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol., 2001, Vol. 113, no. 1, pp. 49-62.

14. Takeda S., Sato N., Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/ non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front. Aging Neurosci., 2014, Vol. 6, 171. doi: 10.3389/fnagi.2014.00171.

15. Tan M.S., Yu J.T., Jiang T., Zhu X.C., Guan H.S., Tan L. IL12/23 p40 inhibition ameliorates Alzheimer’s disease-associated neuropathology and spatial memory in SAMP8 mice. J. Alzheimers Dis., 2014, Vol. 38, no. 3, pp. 633-646.

16. Zou Z., Liu C., Che C., Huang H. Clinical genetics of Alzheimer’s disease. Biomed Res. Int., 2014, Vol. 2014, 291862. doi: 10.1155/2014/291862.


Review

For citations:


Malashenkova I.K., Ogurtsov D.P., Krynskiy S.A., Khailov N.A., Selezneva N.D., Fedorova Ya.B., Ponomareva E.V., Kolykhalov I.V., Gavrilova S.I., Didkovsky N.A. HERPESVIRUS INFECTIONS AND CLINICAL-IMMUNOLOGIC INTERACTIONS IN PATIENTS WITH EARLY-ONSET ALZHEIMER’S DISEASE AND LATE-ONSET ALZHEIMER’S DISEASE. Medical Immunology (Russia). 2021;23(4):805-812. https://doi.org/10.15789/1563-0625-HIA-2168

Views: 469


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)